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Abstract The imbalance in Th17/Treg cell-related responses
plays an important role in the pathogenesis of multiple sclero-
sis (MS). The development of Th17- and Treg cells is regu-
lated by specific transcription factors—RORγt and RORα—
and FOXP3, respectively. The aim was to determine the ex-
pression of RORγt, RORα, and FOXP3 in peripheral blood
mononuclear cells (PBMCs) from MS patients following in
vitro stimulation. The PBMCs from 22 MS patients and 20
healthy subjects were cultured in the presence of 10 μg/ml
MOG, 10 μg/ml PHA, or without stimulation. The PBMCs
were incubated at 37 °C for 24 h, and then the messenger
RNA (mRNA) expression of RORγt, RORα, and FOXP3
was determined by real-time PCR. The expression of
RORγt and RORα was increased in non-stimulated, MOG-
stimulated, and PHA-stimulated PBMCs from MS patients in
comparison with same cultures from the healthy group (P <
0.01, P < 0.01, and P < 0.02 for RORγt; P < 0.001, P < 0.001,
and P < 0.05, for RORα, respectively). The FOXP3 expres-
sion in non-stimulated PBMCs from MS patients was
significantly lower than that in equal culture from healthy
subjects (P < 0.05). There were no significant differences be-
tween healthy subjects and MS patients regarding the expres-
sion of FOXP3 mRNA by MOG-stimulated and PHA-
stimulated PBMCs. These results showed an imbalance in
Th17/Treg cells at transcription factor levels with a deviation
toward Th17 cell in MS. The correction of Th17/Treg balance
at transcription levels should be considered to design novel
therapeutic strategies for MS treatment.
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Introduction
Multiple sclerosis (MS) is an autoimmune-mediated demye-
linating disease of the central nervous system (CNS) (Mahad
et al. 2015). It seems that autoreactive CD4+ T helper (Th)
cells play an important role in the pathological process of MS
(Kostic et al. 2015). Following the antigenic stimulation, var-
ious types of Th cells are differentiated from naïve T cells,
such as Th1, Th2, Th17, or regulatory T (Treg) cells which
were distinguished according to their cytokine patterns
(Raphael et al. 2015). Both IFN-γ-producing Th1 cells and
IL-17-releasing Th17 cells are involved in the development of
MS and its animal model, experimental allergic encephalomy-
elitis (EAE) (Raphael et al. 2015; Volpe et al. 2015). The Treg
cell-related cytokines (TGF-β and IL-10) were associated
with reduction and improvement of MS and EAE symptoms
(Buc 2013; Raphael et al. 2015). The role of Th2 cells, which
secrete high levels of IL-4, IL-5, and IL-13, remains contro-
versial (Raphael et al. 2015).We have previously observed the
elevated concentrations of a Th17-related chemokine
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(CCL20), diminished levels of a Th2/Treg-related chemokine
(CCL22), and unchanged levels of a Treg-related cytokine
(IL-35) in patients with MS (Jafarzadeh et al. 2014a;
Jafarzadeh et al. 2014b; Jafarzadeh et al. 2015).
Th17 cells play an important role in the host defense
against some extracellular pathogens (such as Klebsiella
pneumoniae, Streptococcus pneumoniae, and Candida
albicans) and participate in inflammatory reactions and auto-
immune diseases (Rathore and Wang, 2016; Volpe et al.
2015). The differentiation of Th17 cells from naïve CD4+ T
cells is regulated by cytokines (including IL-6 and TGF-β),
signal transducers (including STAT-3 and Smad), and tran-
scription factors retinoic acid receptor-related orphan recep-
tors (including RORγt and RORα) (Rathore andWang, 2016;
Volpe et al. 2015). The antigenic stimulation of naïve Tcells in
the presence of TGF-β and IL-6 results in the expression of
the RORγt, through STAT-3 and Smad pathways. Both
RORγt and RORα serve as important transcription factors
regulating Th17 cell differentiation (Noack and Miossec
2014; Volpe et al. 2015). The deletion of both RORα and
RORγt genes interrupt the differentiated of naïve CD4+ T
cells to Th17 lymphocytes. However, the deletion of RORγt
gene exhibit stronger consequences on Th17 cell differentia-
tion, suggesting that the RORγt is more important (Noack and
Miossec 2014).
IL-23 is a cytokine inducing TH17 cell maintenance
and full activation. After the initial differentiation of
naïve CD4+ T cells to Th17 cells, subsequent exposure
to IL-23 is needed for the functional maturation and
pathogenic action of Th17 cells (Floss et al. 2015;
Rathore and Wang, 2016). Th17 cells are characterized
by the secretion of several cytokines and chemokines
including IL-17 (also called IL-17A), IL-17F, IL-21, IL-
22, IL-23, IL-26, TNF-α, CCL20, and GM-CSF, al-
though some of these cytokines are not Th17-specific
(Basu et al. 2013; Rathore and Wang, 2016). IL-17 can
influence different cells including endothelial cells, epi-
thelial cells, fibroblasts, myeloid cells, and synoviocytes
(Bedoya et al. 2013; Volpe et al. 2015). IL-17 induces
the secretion of the various inflammatory mediators, in-
cluding IL-8, CXCL1, CXCL6, IL-1β, IL-6, TNF-α,
GM-CSF, MIP-2, and MCP-1 G-CSF (Bedoya et al.
2013; Volpe et al. 2015). The pathogenic role of Th17
cells as well as IL-17 was demonstrated in a number of
autoimmune diseases such as MS, Crohn’s disease, pso-
riasis, and rheumatoid arthritis (Volpe et al. 2015).
Treg cells play an important role in maintaining the periph-
eral tolerance. They can inhibit the function of other effector T
cells and antigen-presenting cells by different mechanisms
such as cell-cell contact and the secretion of suppressive cy-
tokines TGF-β, IL-10, and IL-35 (Rodriguez-Perea et al.
2016). The dysfunction of Treg cells can result in a number
of autoimmune diseases such as SLE and RA (Nie et al. 2015).
Treg cells comprise approximately 5–15 % of the CD4+ T
cells and were divided into two subgroups, including natural
Treg (nTreg) and inducible Treg (iTreg) cells. The nTreg cells
are generated from precursor cells in the thymus and iTreg
cells are differentiated from naïve T cells at peripheral tissues
in the presence of IL-2 and TGF-β (Noack andMiossec 2014;
Rodriguez-Perea et al. 2016). In the periphery, antigenic stim-
ulation of naïve CD4+ T cells in the presence of TGF-β and
IL-2 results in the differentiation of naïve cells into iTreg cells
(Noack and Miossec 2014).
Both nTreg and iTreg cells express master transcription
factor FOXP3 which is encoded by the foxp3 gene on the X
chromosome (Nie et al. 2015; Noack and Miossec 2014). The
Treg cell activity was regulated by the transcription factor
FOXP3, and the mutations of the foxp3 gene disturb the func-
tion of Treg cells, therefore resulting in the development of
various autoimmune diseases (Nie et al. 2015; Noack and
Miossec 2014). The scurfy mice strain exhibit a mutation in
the foxp3 gene, which results in the abnormal expression of
FOXP3. Many mutations in the foxp3 gene have also been
reported in patients with IPEX (immune-dysregulation,
polyendocrinopathy, enteropathy, and X-linked inheritance
syndrome) (Nie et al. 2015).
The balance of Th17/Treg cells regulates the immune
activities and there some evidence suggesting that Th17/
Treg imbalance contributes to the development of various
autoimmune diseases (Noack and Miossec 2014). The re-
sults of a number of investigations were demonstrated that
Th17 cells were increased and the numbers and/or func-
tion of Treg cells were decreased in the peripheral blood
of MS patients, representing an important role of Th17/
Treg cell imbalances in the pathogenesis of MS (Noack
and Miossec 2014). However, the molecular mechanisms
that influence the Th17/Treg imbalances in MS remain
unknown.
The measurement of the transcription factors RORγt,
RORα, and FOXP3 will more objectively reflect Th17/Treg
cell differentiation than the simple measurement of a single
Th17- or Treg cell-related parameter, alone (Lin et al. 2015).
Thus, it is more important to investigate the balance of Th17
and Treg cells at their transcription factor level. Although
there are some reports regarding the transcription factors in
the MS patients or in EAE models (Edstrom et al. 2011;
Martinez et al. 2014), there is no investigation concerning
the measurement of these parameters in PBMCs from MS
patients following the specific and non-specific in vitro stim-
ulation. Thus, this study was conducted to determine the mes-
senger RNA (mRNA) expression of specific transcription fac-
tors of Th17- (RORγt, RORα) and Treg cells (FOXP3) by
PBMCs from newly diagnosed patients with MS following
specific stimulation with MOG, non-specific stimulation with
PHA, or without stimulation to provide new insights regard-
ing the MS immunopathogenesis.
J Mol Neurosci
Material and Methods
Subjects
Blood samples were collected from 22 MS patients (age
35.56 ± 11.16 years; 8 men and 14 women) referring to the
Shephah Hospital of Kerman (a city located in southeast of
Iran). The patients were in the RRMS courses of disease. The
presence of MS was confirmed by expert neurologists accord-
ing to the clinical and paraclinical findings (MRI study,
oligoclonal bands in CSF, and evoked potentials) based on
McDonald’s criteria (McDonald et al. 2001). All patients were
newly diagnosed and none of them received treatment before
blood sample collection.
In total, 20 healthy subjects (age 36.45 ± 11.73 years;
8 men and 12 women) were also enrolled in the study as
a control group. The healthy individuals were recruited
among blood donors of the Blood Transfusion
Organization of Kerman and interviewed concerning the
CNS disorders and none of them had CNS or other rel-
evant disease. All control subjects were basically in good
health, with no acute or chronic illnesses. Those with
diseases (including a history of recurrent infections, asth-
ma, allergy and atopic diseases, any suspected immuno-
logical diseases, and malignancy), smoking, medication,
surgery, and major trauma within 6 months prior to
b lood co l l e c t i on were a l l exc luded f rom the
investigation.
This study evaluated and approved by the Ethical
Committee of Kerman University of Medical Sciences.
Moreover, participants were enrolled into the study if they
agreed and informed written consent was also obtained from
all of them. A peripheral blood sample (5 ml) was obtained
from all participants, and the PMBCs were separated for more
analysis.
In Vitro Stimulation of PBMCs
The PBMCs were isolated from heparinized peripheral
blood by gradient centrifugation over Lymphosep
(Biosera, UK). The separated PBMCs were washed three
times and then were resuspended in a RPMI-1640 medi-
um (Gibco Life Technologies Ltd, Paisley, UK) supple-
mented with 10 % heat inactivated fetal bovine serum
(Gibco Life Technologies Ltd, Paisley, UK) and antibi-
otics, including penicillin (100 U/ml) and streptomycin
(100 μg/ml). The cells were then cultured at 1 × 106
cells/ml in 24-well sterile flat-bottomed microtiter plates
(Nunc, Thermo Fisher Scientific Inc, Denmark) in the
presence of 10 μg/ml MOG [(35–55) human; Anaspec,
USA], 10 μg/ml phytohemagglutinin mitogen (PHA)
(Gibco Life Technologies Ltd, Paisley, UK)] as positive
control or without any stimulation as negative control.
The PBMCs were cultured at 37 °C in a 5 % CO2 incu-
bator for 24 h. After this period, the PBMCs were har-
vested for total RNA extraction.
RNAExtraction, Reverse Transcription, and Quantitative
Real-Time PCR
Total RNAwas extracted from cultured PBMCs by using the
Trizol reagent (Bionner, Korea) according to the manufac-
turer’s guidelines. To prevent the amplification of contaminat-
ing genomic DNA, extracted RNAwas treated with DNase I
(Thermo Scientific, EU). The quality and purity of the extract-
ed RNA was determined by electrophoresis on an ethidium
bromide pre-treated agarose gel together with the measure-
ment of absorption by spectrophotometer and calculation of
260/280 ratio. The RNA was converted to complementary
DNA (cDNA) using a cDNA synthesis kit (Bionner, Korea)
with both oligo (dT) and random hexamer primers. The ex-
pression of the RORγt, RORα, and FOXP3 in the cultured
PBMCs was determined by real-time PCR. The β-actin gene
was used as a housekeeping control. The primers used are
demonstrated in Table 1.
The reverse transcription was performed according to the
following protocol: 70 °C for 10 min (without reverse tran-
scription enzyme), −20 °C for 1 min (cooling step), addition of
reverse transcription enzyme, 42 °C for 60 min, and the pro-
tocol was finished by a final step at 95 °C for 10min to halt the
activation of the reverse transcription enzyme.
The real-time PCR method was performed by using a
SYBR green master mix (Bionner, Korea), combined with
200 ng of template cDNA with the appropriate primers
(Table 1) in a real-time PCR System (Applied Biosystems,
USA) using the following program: 1 cycle of 95 °C for
15 min, 40 cycles of 95 °C for 30 s, 60 °C for 30 s, and finally
72 °C for 30 s. Primers were synthesized by the Bionner
company (Korea). The relative mRNA expression of tran-
scription factors was normalized by β actin as a housekeeping
gene and calculated by the 2-ΔΔCt formula. The melting
Table 1 The used primers for the gene expression of RORγt, RORα,
and FOXP3 by PBMC from healthy subjects and MS patients
Gene Primer
RORγt Forward: 5-TGGAAGTGGTGCTGGTTAGGATG-3
Reverse: 5-GGAGTGGGAGAAGTCAAAGATGGA-3
RORα Forward: 5-CTACATTGACGGGCACACC-3
Reverse: 5-ACACAGTTGGGGAAGTCTCG-3
FOXP3 Forward: 5-AGAAGCAGCGGACACTCAAT-3
Reverse: 5-CACTTGTGCAGACTCAGGTTGT-3
β-Actin Forward: 5-GCATGGGTCAGAAGGATTC-3
Reverse: 5-GTCCCAGTTGGTGACGAT-3
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curves and quantitative analyses of the data were performed
using Applied Biosystems software version 1.1.308.111
(USA). PCR products were also analyzed by electrophoresis
and visualized on a 1 % agarose gel containing 0.5 mg/ml
ethidium bromide.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analysis was
performed by using ANOVA, t test, Kruskal-Wallis, and
Mann-Whitney U tests, as appropriate. The P values of less
than 0.05 were considered statistically significant.
Results
The Expression of Th17 Cell-Specific Transcription
Factor RORγt by PBMCs
The fold change expression of transcription factors, by non-
stimulated, MOG-stimulated, and PHA-stimulated PBMCs
from healthy subjects and MS patients are demonstrated in
Table 2.
In the healthy control group, the mRNA expression of
RORγt in PHA-stimulated PBMCs was significantly higher
than those inMOG-stimulated and non-stimulated PBMCs (P
< 0.03 and P < 0.01, respectively). No significant difference
was observed between non-stimulated and MOG-stimulated
PBMCs, regarding themRNA expression of RORγt, although
this parameter was higher in MOG-stimulated PBMCs
(Table 1).
In MS patients, the expression of RORγt mRNAwas sig-
nificantly up-regulated in PHA- and MOG-stimulated
PBMCs in comparison with non-stimulated PBMCs (P <
0.01 and P < 0.04, respectively). There were no significant
differences between PHA-stimulated and MOG-stimulated
PBMCs regarding the gene expression of RORγt, although
this parameter was higher in a PHA-stimulated culture
(Table 1).
The mRNA expression of RORγt in non-stimulated,
MOG-stimulated, and PHA-stimulated PBMCs from MS pa-
tients was significantly higher than that in counterpart cultures
from the healthy control group (P < 0.01, P < 0.01, and P <
0.02, respectively) (Fig. 1).
The Expression of Th17 Cell-Specific Transcription
Factor RORα by PBMCs
In the healthy group, the expression of RORα mRNA in
PHA-stimulated PBMCs was significantly increased as com-
pared withMOG-stimulated and non-stimulated PBMCs (P <
0.001 and P < 0.001, respectively). There was no significant
difference between non-stimulated and MOG-stimulated cul-
tures, with respect to the expression of RORα, although this
parameter was higher in MOG-stimulated PBMCs.
In patients with MS, the expression of RORα mRNAwas
significantly up-regulated in PHA- and MOG-stimulated
PBMCs in comparison with non-stimulated PBMCs (P <
0.04 and P < 0.04, respectively). In MS patients, the expres-
sion of RORα mRNAwas also significantly up-regulated in
PHA-stimulated PBMCs in comparison with a MOG-
stimulated culture (P < 0.05) (Table 1).
The expression of RORα in non-stimulated, MOG-stimu-
lated, and PHA-stimulated PBMCs from MS patients were
significantly higher than those in the same cultures from the
healthy control group (P < 0.001, P < 0.001, and P < 0.05, re-
spectively) (Fig. 2).
The Expression of Treg Cell-Specific Transcription Factor
FOXP3 by PBMCs
In the healthy group, the PHA-induced expression of FOXP3
in PBMCs was significantly higher than non-stimulated and
MOG-induced cultures (P < 0.03 and P < 0.04, respectively).
There was no significant difference between the non-
stimulated and MOG-stimulated PBMCs, concerning the ex-
pression of FOXP3 (Table 2).
In MS patients, the expression of FOXP3 in MOG-
stimulated and PHA-stimulated cultures were significantly
higher than those in non-stimulated PBMCs (P < 0.01 and P
< 0.01, respectively). The PHA-induced expression of FOXP3
was also significantly increased as compared with MOG-
stimulated PBMCs (P < 0.05) (Table 2).
The expression of FOXP3 mRNA in non-stimulated
PBMCs from MS patients was significantly lower than that
Table 2 The expression of
RORγt, RORα, and FOXP3 by
PBMC from healthy subjects and
MS patients
Groups Stimulator of PBMC RORγt expression RORα expression FOXP3 expression
Healthy group Without stimulation 1.00 ± 0.36 1.00 ± 0.44 1.00 ± 0.45
MOG 2.26 ± 0.96 1.32 ± 0.53 0.87 ± 0.33
PHA 5.10 ± 1.04 15.29 ± 2.91 7.54 ± 3
MS patients Without stimulation 3.66 ± 1.18 11.55 ± 4.17 0.24 ± 0.16
MOG 11.23 ± 3.32 29.42 ± 7.59 1.36 ± 0.30
PHA 15.81 ± 4.43 68.06 ± 17.57 4.70 ± 1.67
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in equal culture from the healthy control group (P < 0.05)
(Fig. 3). The differences in the expression levels of FOXP3
mRNA byMOG-stimulated and PHA-stimulated PBMCs be-
tween healthy subjects and MS patients were not statistically
significant (Fig. 3).
Discussion
The results of this study showed that in both healthy subjects
and MS patients, the expression of RORγt, RORα, and
FOXP3 in PHA-stimulated PBMCs was significantly
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enhanced as compared with non-stimulated cultures. The
PHA was used as a positive control inducer, and its effects
can be ascribed to the polyclonal activation of T cells, which
induces the differentiation of naïve CD4+ T cells into various
effector T cells including Th17 and Treg cells. In healthy sub-
jects, no significant difference was observed between non-
stimulated and MOG-stimulated PBMCs, regarding the ex-
pression of RORγt and RORα, whereas in MS patients these
parameters were increased in MOG-stimulated cultures. This
difference may be due to the prior in vivo sensitization of T
cells to myelin antigens (such as MOG) in MS patients.
The expression of RORγt and RORα in non-stimulat-
ed, MOG-stimulated, and PHA-stimulated PBMCs from
MS patients were significantly higher than those in the
same PBMC cultures from the healthy control group.
RORγt and RORα are two transcription factors directly
mediating Th17 differentiation. Indeed, RORα in a syn-
ergic manner with RORγt enhances IL-17A production
(Wang et al. 2013). Our findings represent that the fre-
quency of MOG-specific Th17 cells in MS patients may
be higher than that in controls. In accordance with our
findings, high frequencies of autoreactive Th17 cells
have been indicated in the CNS of MS patients and
EAE mice (Becher and Segal 2011). The high IL-17
levels in the cerebrospinal fluid (CSF) of patients with
MS also represent the involvement of this cytokine in the
pa thogenes i s o f d i sease (Kos t i c e t a l . 2014) .
Furthermore, RORγt deficiency leads to more resistance
to EAE induction (Raphael et al. 2015). It has been also
indicated that the IL-17-deficient mice display a delayed
onset, lower EAE scores, and lower histological alter-
ations with early recovery from disease (Raphael et al.
2015). Moreover, the higher expression of RORγt and
RORα by PHA-stimulated PBMCs from MS patients
represent an elevated capacity to generate Th17 cell-
related immune responses in these subjects.
The possible mechanisms by those IL-17 is involved in
immunopathogenesis of MS may be through the recruitment
of neutrophils into the inflammatory sites, induction of the
reactive oxygen species (ROS) production in brain endothelial
cells, activation of microglia cells to produce pro-
inflammatory cytokines and mediators, and the stimulation
of astrocytes to produce CXC chemokines (Volpe et al.
2015). Elevated expression ofmatrixmetalloproteinases (such
as MMP-2, MMP3, MMP-7, and MMP-9) have been also
reported in the CNS of MS patients (Mirshafiey et al. 2014).
Some TH17 cell-derived cytokines (such as TNF-α) trigger
the expression of matrix metalloproteinases, which may have
a crucial role in the rupture of blood brain barrier (BBB)
(Mirshafiey et al. 2014; Volpe et al. 2015).
The results of the present study showed that the expression
of FOXP3 in non-stimulated PBMCs from MS patients was
significantly lower than that in the same culture from the
healthy control group. FOXP3 plays a fundamental role in
the differentiation of the Treg cells while suppressing the de-
velopment of Th17 cells (Noack and Miossec 2014). These
findings were indicated that the downregulation of Treg cell-
related immune responses may contribute to the MS
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pathogenesis. No significant differences were observed be-
tween healthy subjects and MS patients regarding the expres-
sion of FOXP3 by MOG-stimulated and PHA-stimulated
PBMCs. These findings may represent that there is no intrin-
sic defect in Treg cells inMS patients. It seems that the in vivo
conditions in MS patients may have suppressive effects on the
Treg cell activity. Therefore, in a culture environment, the
inhibitory effects of in vivo conditions on Treg cell function
may be eliminated and they will normally respond to in vitro
antigenic stimulation. Interestingly, it has been demonstrated
that the plasma exchange can increase the FOXP3/RORγt
expression in patients with MS which is in accordance with
our results (Jamshidian et al. 2015).
The results of this study also showed that in MS pa-
tients, the expression of FOXP3 in MOG-stimulated cul-
ture was significantly higher than that in non-stimulated
PBMCs. Accordingly, the normal activity was exhibited
by Treg cells after in vitro stimulation that represent that
the extrinsic parameters may influence the Treg cell ac-
tivity in the MS patients. There are some investigations
concerning the number and/or function of Treg cells in
MS patients with controversial results. Both decreased
and unchanged in the number of Treg cells are reported
in the peripheral blood of MS patients (Kostic et al.
2015). A number of in vitro studies have reported the
impaired immunosuppressive function of Treg cells. It
has been also reported that Treg cells isolated from MS
patients had low inhibitory effects on myelin antigen-
induced specific T cell proliferation in comparison with
healthy subjects. Moreover, Treg obtained in the relapse
phase of the MS exhibit impaired suppressor function,
whereas Tregs collected during the remission phase dis-
play normal immunosuppressive activity (Shichita et al.
2009). These discrepancies may be largely attributed to
the heterogeneity of Treg cell population, using of dif-
ferent markers of Treg cells in the studies and different
inclusion criteria for MS patients.
The existence of the balance between Th17 and Treg cell-
related immune responses are very important for maintaining
the normal immunological functions. The occurrence of the
imbalance between Th17/Treg cell-related immune responses
may cause a number of disorders such as cancer, autoimmu-
nity, allergy, and infectious diseases (Zhang et al. 2014). The
results of the present study indicate that there is an imbalance
in Th17/Treg cells at transcription factor levels with a tenden-
cy toward Th17 cell-related parameters in MS patients which
may contribute to the pathogenesis of disease.
It should be noted that Th17 and Treg cells have op-
posite activities in the development of autoimmune and
inflammatory diseases. The Th17 cells tend to potentiate
autoimmunity, whereas Treg cells control it and therefore
play a very important preventive role against autoimmu-
nity by controlling the activation of autoreactive CD4+ T
effector cells (Noack and Miossec 2014). The differenti-
ation process of Th17 and Treg cells is nearly related.
TGF-β induces the expression of both FOXP3 and
RORγt in naïve CD4+ T cells, but the presence or the
absence of IL-6 will be determined by the differentiation
of naïve T cells toward Treg or Th17 cells. The antigenic
stimulation of naïve CD4+ T cells in the presence of
TGF-β alone (in the absence of IL-6) result in the ex-
pression of FOXP3 whereas the expression of RORγt is
suppressed; therefore, Treg cell-related response is dom-
inant (Ivanova and Orekhov, 2015; Murphy and
Stockinger, 2010). TGF-β is not capable to initiate the
Th17 differentiation unless IL-6 is present. When IL-6 is
present, the TGF-β-induced FOXP3 expression is re-
duced and RORγt expression is up-regulated (Ivanova
and Orekhov 2015; Noack and Miossec 2014). Higher
levels of IL-6 have been reported in patients with MS
(Chen et al. 2012), which may be responsible for the
Th17/Treg imbalance in these subjects. The Th17 and
Treg cells also antagonize each other functionally. For
instance, FOXP3 suppresses RORγt activation by a
physical interaction while IL-6/STAT3 axis suppresses
FOXP3 expression (Ichiyama et al. 2008).
As mentioned, the Th17/Treg imbalance was associat-
ed with the development and progression of MS. The
correcting of Th17/Treg imbalance in MS may consider
for designing of novel and effective immunotherapies
which can be done at different levels such as cytokines,
receptors, or signaling pathways. The STAT3 and STAT5
are two signaling factors which control the differentiation
of Th17 and Treg cells, respectively. It has been reported
that the inhibition of STAT3 by siRNA significantly de-
creases the proportion of Th17 cells and increases the
proportion of Treg cells, among the CD4+ T cell popu-
lation from patients with rheumatoid arthritis (Noack and
Miossec 2014). Similar immunotherapeutics by targeting
transcription factors such as RORγt, RORα, and FOXP3
can present novel therapeutic strategies for the control of
inflammation in MS patients.
In conclusion, the results of the present study indicated that
the expression of RORγt and RORα were increased in non-
stimulated, MOG-stimulated, and PHA-stimulated PBMCs
from MS patients. However, the expression of FOXP3
mRNA was decreased in the non-stimulated PBMCs from
MS patients. There were no significant differences between
healthy subjects and MS patients regarding the expression of
FOXP3 mRNA by MOG-stimulated and PHA-stimulated
PBMCs. These results indicate an imbalance of Th17/Treg
cells at transcription factor levels and a Th17 cell biased pat-
tern in MS patients. The correction of Th17/Treg cells imbal-
ance at transcription factor levels may consider in designing of
the novel therapeutic strategies for treatment of MS in the
future investigations.
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